The National Agency for Food and Drug Administration and Control (NAFDAC) has debunked a video circulating on social media alleging that the Agency has secretly banned the sale and use of Amoxicillin in Nigeria.

"This claim is false and devoid of any factual basis. NAFDAC has not banned Amoxicillin in Nigeria, either secretly or openly. As a responsible regulatory authority, the Agency publicly notifies Nigerians of any regulatory actions through official channels. NAFDAC alerts the public through its Recalls, Safety Alerts, Blacklists, and other safety notices of any substandard, falsified, or affected products requiring regulatory action," NAFDAC said in a statement signed by the Director-General, Mojisola Adeyeye.

The agency said these safety communications clearly outline the specific product names, batch numbers, manufacturers, and the necessary measures to be taken. They provide critical information that may impact treatment and diagnostic decisions for healthcare providers and patients. Blacklisting, where applicable, involves prohibiting specific companies from the sale, distribution, or use of their products due to safety concerns, regulatory violations, or unethical practices.

In recent months, NAFDAC issued targeted safety alerts on certain brands and batches of Amoxicillin. In August 2025, Public Alert No. 24/2025 announced the recall of Amoxivue (Amoxicillin) 500mg capsules due to low Active Pharmaceutical Ingredient (API) content. In October 2025, Public Alert No. 34/2025 addressed substandard batches of Astamocil and Astamentin suspensions, while Public Alert No. 35/2025 notified the public of substandard batches of Annmox and Jawamox suspensions. These actions were specific to identified products and do not constitute a ban on Amoxicillin.

"Members of the public are advised to disregard the misleading video and rely only on verified Recalls and Safety Alerts published on the official NAFDAC website: https://nafdac.gov.ng/category/recalls-and-alerts/. NAFDAC remains committed to safeguarding public health through transparent, science-based regulatory actions," NAFDAC said.

ASA